Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,374.00
  • Today's Change34.00 / 1.02%
  • Shares traded773.23k
  • 1 Year change-5.44%
  • Beta0.9261
Data delayed at least 20 minutes, as of Jun 01 2023 17:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

On Thursday, Dechra Pharmaceuticals PLC (DPH:LSE) closed at 3,374.00, -15.65% below its 52-week high of 4,000.00, set on Apr 14, 2023.
52-week range
Today
2,473.32Mar 13 20234,000.00Apr 14 2023
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open3,354.00
High3,506.00
Low3,346.00
Bid2,940.00
Offer3,800.00
Previous close3,340.00
Average volume1.11m
Shares outstanding113.88m
Free float112.78m
P/E (TTM)93.04
Market cap3.80bn GBP
EPS (TTM)0.359
GBP
Annual div (ADY)45.39
GBX
Annual div yield (ADY)1.36%
Div ex-dateMar 09 2023
Div pay-dateApr 13 2023
Data delayed at least 20 minutes, as of Jun 01 2023 17:30 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Dechra Pharmaceuticals PLC shares was Hold at 3.00 on 05 Sep 2022Read the full article

Board of Directors

1/9

Alison Platt, Non-Executive Chairman

2/9

Ian Page, Chief Executive Officer

3/9

Paul Sandland, Chief Financial Officer

4/9

Tony Griffin, Managing Director, Dechra Veterinary Products EU

5/9

Ishbel Macpherson, Non-Executive Director

6/9

Dr Lawson Macartney, Senior Independent Non-Executive Director

7/9

Lisa Bright, Non-Executive Director

8/9

John Shipsey, Non-Executive Director

9/9

Geeta Gopalan, Non-Executive Director

Contact

Address:
Dechra Pharmaceuticals PLC
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

T: +44 (0) 1606 814730
F: +44 (0) 1606 814731
E: corporate.enquiries@dechra.com

Chief Executive Officer: Ian Page
Chief Financial Officer: Paul Sandland
Head of Investor Relations: Jonny Armstrong

Financial PR Advisors:
TooleyStreet Communications Ltd

Registered Office: 
15 Colmore Row, 
Birmingham, 
B3 2BH.

2023 Half-Year Results

An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.